Endobronchial Ultrasound Biopsy Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

The Endobronchial Ultrasound Biopsy Market is expected to reach US$ 1.27 billion by 2033 from US$ 820 million in 2024, with a CAGR of 5.03% from 2025 to 2033. One of the main factors propelling the market's growth is the increasing prevalence of diseases requiring endoscopic ultrasound treatments.

Global Endobronchial Ultrasound Biopsy Industry Overview

The market for endobronchial ultrasound (EBUS) biopsies is expanding significantly due to factors such as the rising incidence of lung cancer, improvements in minimally invasive diagnostic technologies, and the growing need for accurate pulmonary disease staging and diagnosis. With better safety profiles and quicker patient recovery periods, EBUS offers a less intrusive substitute for conventional surgical biopsies. In peripheral or hard-to-reach lesions, the technique is notably useful for identifying and staging non-small cell lung cancer (NSCLC) and other thoracic malignancies. Further driving market expansion are technological advancements like improved imaging capabilities and the creation of specialized biopsy instruments. In order to satisfy the rising demand for EBUS biopsy operations, major companies in the market such as Cook Medical, Boston Scientific, Medtronic, and Olympus Corporation are actively engaged in clinical research and product development.

This increase may be ascribed to a number of factors, including the increased incidence of cancer, the development of endobronchial ultrasonography (EBUS) technology, the aging of the population, the rise in respiratory illnesses, and the expanding use of less invasive procedures. The WHO projects that by 2030, there will be 1.4 billion people worldwide who are 60 years of age or older, up from an estimated 1.1 billion in 2021.

Since lung cancer is one of the main causes of cancer-related deaths globally and its incidence rates are rising due to factors including smoking, air pollution, and occupational risks, the market for endobronchial ultrasound biopsies is growing as a result of its increased prevalence. For example, according to the American Cancer Society, there will be about 226,650 new cases of lung cancer in the United States in 2025, with 110,680 instances in men and 115,970 in women. Additionally, it is projected that lung cancer would cause about 124,730 fatalities, with 60,540 women and 64,190 men affected. The need for less invasive techniques like EBUS-guided biopsy is rising as a timely and precise diagnosis is essential to bettering patient outcomes. Lung cancer can be detected and staged early because to this technique's accurate lymph node and lung lesion sampling.

Additionally, a major factor in the market's expansion is the growing incidence of respiratory conditions including TB and chronic obstructive pulmonary disease (COPD). The need for minimally invasive diagnostic techniques has grown since these disorders are becoming more common as a result of smoking, air pollution, and aging populations. Furthermore, improvements in EBUS technology, including as real-time needle guiding and improved imaging resolution, improve diagnostic effectiveness and are accelerating its use by healthcare professionals.

Growth Drivers for the Endobronchial Ultrasound Biopsy Market

Rising Incidence of Lung Cancer

One of the main causes of cancer-related fatalities worldwide is still lung cancer, especially non-small cell lung cancer (NSCLC). Effective diagnostic techniques are becoming more and more necessary due to the disease's high incidence in order to identify and stage it early. EBUS-guided biopsies are becoming essential instruments for accomplishing this objective. EBUS contributes to better diagnosis and staging, which are crucial for choosing the best course of therapy, by providing a less intrusive and more precise method of taking tissue samples from lung lesions. The need for EBUS operations as part of complete diagnostic paths is increasing due to the global rise in lung cancer incidence, which is propelling the market ahead.

Shift Toward Minimally Invasive Procedures

Healthcare professionals now prioritize less invasive techniques, particularly when diagnosing cancer. Conventional surgical biopsies frequently result in increased hospital stays, danger, and recuperation periods. A safer and more effective substitute is endobronchial ultrasonography (EBUS), which gives real-time imaging guidance to precisely biopsy lung tissue with the least amount of patient pain and danger. With a quicker recovery and fewer complications than traditional surgical techniques, EBUS has emerged as the go-to option for identifying and staging diseases like lung cancer. The market for EBUS operations is growing as a result of the healthcare industry's growing preference for methods that reduce invasiveness, patient downtime, and medical expenses.

Increasing Adoption in Emerging Markets

A number of important variables are driving the growing use of endobronchial ultrasound (EBUS) biopsy in emerging regions. More hospitals and diagnostic facilities in developing nations are outfitted with cutting-edge medical technology, such as EBUS systems, as the infrastructure for healthcare develops. Government programs and expenditures to improve healthcare quality and accessibility are making this growth possible. Furthermore, the need for precise and early detection techniques is being driven by growing awareness of lung cancer and its increasing prevalence in these areas. The market for these technologies is growing as more doctors and patients realize the advantages of less invasive treatments like EBUS. The market is expanding significantly as a result of this move to more contemporary diagnostic techniques, particularly in areas where cancer rates are on the rise.

Challenges in the Endobronchial Ultrasound Biopsy Market

High Equipment Costs

The high expense of buying and maintaining the required equipment is one of the major obstacles preventing endobronchial ultrasound (EBUS) biopsy from becoming widely used. Since EBUS systems need a significant upfront investment, many smaller clinics or hospitals with tighter budgets can find it difficult to justify the cost. The cost is increased by the requirement for specialized probes, accessories, and continuing maintenance in addition to the initial outlay. In order for medical personnel to use these tools efficiently, healthcare providers also need to make ongoing training investments. These elements work together to make EBUS technology an expensive investment, especially in environments with limited resources. As a result, its usage may be limited to bigger, more established healthcare facilities or its acceptance may be delayed.

Limited Availability of Trained Personnel

Trained pulmonologists and technicians that are proficient in both utilizing the equipment and deciphering intricate imaging data are among the qualified staff needed for EBUS biopsy treatments. Unfortunately, there is a lack of qualified healthcare workers, particularly in rural areas and emerging markets. The adoption and efficient usage of EBUS technologies are hampered by the shortage of qualified staff. The competence and experience of the operator are crucial to the success of an EBUS operation, and the quality of the diagnostic results may deteriorate in the absence of adequate training. Consequently, this scarcity may lead to uneven results, impede prompt diagnosis, and postpone patient care, so hindering the expansion of the EBUS biopsy industry.

United States Endobronchial Ultrasound Biopsy Market

The market for endobronchial ultrasound (EBUS) biopsies in the US is expanding quickly due to the rising incidence of lung cancer and the increased need for less invasive diagnostic techniques. Lung cancer and other pulmonary disorders can be precisely staged and diagnosed with EBUS, a less invasive option to standard biopsy techniques. The process is crucial for precise diagnosis and treatment planning because it can reach hard-to-reach lesions and offer real-time imaging guidance. Its market expansion is also aided by developments in ultrasound technology and the increasing use of EBUS by medical professionals. The United States is positioned as a leader in the worldwide EBUS biopsy market thanks to its robust healthcare system, high levels of medical innovation, and a well-established regulatory framework.

One of the main factors driving the use of EBUS in diagnosis and staging is the rising incidence of lung cancer. It is anticipated that the growing number of lung cancer cases would fuel market expansion. The American Cancer Society (ACS) Cancer Statistics 2024, for example, projects that 2 million new instances of cancer would be detected in the US in 2024, up from 1.9 million in 2023. Lung and bronchus cancer are predicted to account for 234.5 thousand of the total cancer cases in 2024. Compared to conventional surgical biopsies, EBUS provides a less intrusive method of obtaining tissue samples. Therefore, since endobronchial ultrasonography biopsy is a minimally invasive treatment that can be carried out with local anesthetic and moderate sedation, the increasing number of lung cancer patients in the area is anticipated to drive the need for this operation.

United Kingdom Endobronchial Ultrasound Biopsy Market

The market for endobronchial ultrasound (EBUS) biopsies is expanding in the UK due to the rising incidence of lung diseases and the need for less intrusive diagnostic techniques. Lung cancer and other pulmonary disorders can be precisely staged and diagnosed with EBUS, a less invasive option to standard biopsy techniques. The adoption of EBUS operations is facilitated by the UK's strong healthcare system, comprehensive payment regulations, and an increasing emphasis on cutting-edge diagnostic technology. The broad use of EBUS in some areas, however, may be hampered by issues including the high expense of equipment and the requirement for specific training for medical personnel. Despite these obstacles, the market is anticipated to grow as demand for EBUS biopsy treatments is driven by rising awareness and technical advances.

India Endobronchial Ultrasound Biopsy Market

The market for endobronchial ultrasound (EBUS) biopsies in India is expanding significantly due to the rising incidence of lung diseases and improvements in diagnostic technology. EBUS use in clinical settings is being aided by the nation's growing healthcare infrastructure as well as growing knowledge of the advantages of minimally invasive treatments. In order to accurately stage and diagnose lung cancer and other respiratory disorders, hospitals and specialist clinics are increasingly using EBUS. The use of cutting-edge diagnostic technologies like EBUS is further supported by government programs targeted at improving healthcare access and quality. Nevertheless, obstacles like the high expense of equipment and the requirement for specific training for medical personnel might hinder the broad adoption of EBUS in every area.

Saudi Arabia Endobronchial Ultrasound Biopsy Market

The market for bicycles in the United Arab Emirates (UAE) is expanding significantly due to government The market for endobronchial ultrasound (EBUS) biopsies in Saudi Arabia is expanding due to the rising incidence of lung diseases and improvements in diagnostic technology. EBUS use in clinical settings is being aided by the nation's growing healthcare infrastructure as well as growing knowledge of the advantages of minimally invasive treatments. In order to accurately stage and diagnose lung cancer and other respiratory disorders, hospitals and specialist clinics are increasingly using EBUS. The use of cutting-edge diagnostic technologies like EBUS is further supported by government programs targeted at improving healthcare access and quality. Nevertheless, obstacles like the high expense of equipment and the requirement for specific training for medical personnel might hinder the broad adoption of EBUS in every area.

Recent Developments in Endobronchial Ultrasound Biopsy Industry

• In response to growing demand, GE Healthcare said in October 2024 that it would be expanding its manufacture of medical imaging equipment, including MRI and ultrasound devices, in Waukesha County, Wisconsin, in the United States. In response to the increasing demand for cutting-edge equipment in hospitals and clinics throughout the globe, the expansion seeks to improve healthcare delivery and innovation.
• FUJIFILM Healthcare Europe GmbH said in September 2024 that their ARIETTA 750 FF ENDO ultrasound system is compatible with a linear bronchoscope and several ultrasound endoscopes. This system has cutting-edge technology including Praxis's EndoCore EBUS-TBNA biopsy equipment, which aims to improve the precision and effectiveness of lung biopsies, was approved by the FDA in October 2023. By enabling better tissue sampling during endobronchial ultrasonography operations, this cutting-edge equipment seeks to enhance patient outcomes.

Endobronchial Ultrasound Biopsy Market Segmentation

Product

• EBUS Scopes
• EBUS Needles
• Ultrasound Processors and Imaging Systems
• Accessories

Application

• Cancer Diagnostic
• Infection Diagnostic
• Others

End Use

• Hospitals
• Ambulatory Surgical Centers (ASCs)
• Specialty Clinics

Country

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

The key players have been analyzed by:

• Overview
• Key Persons
• Recent Development & Strategies
• Revenue Analysis

Key Players Analyzed:

• GE Healthcare
• Siemens Healthcare Private Limited
• Koninklijke Philips N.V.
• Boston Scientific Corporation
• Olympus Corporation
• Cook Group Incorporated
• FUJIFILM Holdings Corporation
• Medi-Globe Technologies GmbH